NASDAQ:TROV - TrovaGene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.7640 +0.03 (+4.09 %)
(As of 07/18/2018 06:00 AM ET)
Previous Close$0.7298
Today's Range$0.72 - $0.7998
52-Week Range$0.72 - $13.80
Volume2.14 million shs
Average Volume716,095 shs
Market Capitalization$3.69 million
P/E Ratio-0.12
Dividend YieldN/A
TrovaGene logoTrovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio2.03
Quick Ratio2.03


Trailing P/E Ratio-0.12
Forward P/E Ratio-0.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales7.56
Cash FlowN/A
Price / CashN/A
Book Value$1.48 per share
Price / Book0.52


EPS (Most Recent Fiscal Year)($6.48)
Net Income$-24,900,000.00
Net Margins-3,861.57%
Return on Equity-342.47%
Return on Assets-134.39%


Outstanding Shares4,950,000
Market Cap$3.69

The Truth About Cryptocurrencies

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

When did TrovaGene's stock split? How did TrovaGene's stock split work?

Shares of TrovaGene reverse split on Monday, June 4th 2018. The 1-12 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 1st 2018. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 8 shares after the split.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) released its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.44) by $0.36. The medical research company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.10 million. TrovaGene had a negative net margin of 3,861.57% and a negative return on equity of 342.47%. View TrovaGene's Earnings History.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for TrovaGene.

What price target have analysts set for TROV?

3 equities research analysts have issued twelve-month target prices for TrovaGene's stock. Their predictions range from $7.00 to $48.00. On average, they anticipate TrovaGene's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 3,499.5% from the stock's current price. View Analyst Ratings for TrovaGene.

What is the consensus analysts' recommendation for TrovaGene?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (6/7/2018)
  • 2. Maxim Group analysts commented, "Trovagene announces the initiation of its Phase 2 clinical trial, evaluating the combination of PCM-075 and Zytiga in patients with metastatic Castration- Resistant Prostate Cancer (mCRPC). The study will enroll n=25 patients with mCRPC who are showing early signs of disease progression while on abiraterone/prednisone therapy and will evaluate the proportion of patients achieving disease control after 12 weeks of study treatment. Trovagene still needs to raise capital. The company raised $4.5M in December last year, not enough to achieve critical mass. We downgraded the stock (Nov. 10, 2017) on anticipation that the raise would be dilutive. So while we fundamentally believe in PCM-075, a weak balance sheet still needs to be addressed before we could be more constructive on the outlook for the company." (1/24/2018)

Who are some of TrovaGene's key competitors?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:
  • Dr. Thomas H. Adams, Interim CEO & Chairman of the Borad (Age 75)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 58)
  • Ms. Elizabeth Anderson CPA, VP of Fin. and Admin.
  • Mr. George Samuel J.D., VP & Gen. Counsel
  • Ms. Vicki Kelemen, Sr. Director of Communications

Has TrovaGene been receiving favorable news coverage?

Media headlines about TROV stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TrovaGene earned a media sentiment score of 0.08 on Accern's scale. They also gave headlines about the medical research company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $0.7640.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $3.69 million and generates $500,000.00 in revenue each year. The medical research company earns $-24,900,000.00 in net income (profit) each year or ($6.48) on an earnings per share basis. TrovaGene employs 17 workers across the globe.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]

MarketBeat Community Rating for TrovaGene (NASDAQ TROV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  403
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.